SEC Comment Letter 0000000000-23-002526 to Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: March 15, 2023 · CIK: 0001643918 · Accession: 0000000000-23-002526
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270353
Letter
United States securities and exchange commission logo March 15, 2023 Stephen Stamp Chief Executive Officer Midatech Pharma Plc 850 Library Ave., Suite 204 Newark , Delaware 19711 Re:Midatech Pharma Plc Registration Statement on Form F-1 Filed March 8, 2023 File No. 333-270353 Dear Stephen Stamp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jason McCaffrey, Esq.
Show Raw Text
United States securities and exchange commission logo
March 15, 2023
Stephen Stamp
Chief Executive Officer
Midatech Pharma Plc
850 Library Ave., Suite 204
Newark , Delaware 19711
Re:Midatech Pharma Plc
Registration Statement on Form F-1
Filed March 8, 2023
File No. 333-270353
Dear Stephen Stamp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jason McCaffrey, Esq.